WCLC 2017: Updated Results of Nivolumab and Chemotherapy in Advanced Non–Small Cell Lung Cancer
Posted: Tuesday, October 24, 2017
A 3-year update of CheckMate 012, research that analyzed the safety and efficacy of nivolumab plus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced non–small cell lung cancer (NSCLC), reported benefits in terms of response and overall survival. In fact, prolonged survival regardless of programmed cell death ligand 1 expression was observed in a subset of patients. Rosalyn J. Juergens, MD, PhD, of McMaster University, Hamilton, Ontario, Canada, presented these updates at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract OA 17.03) in Yokohama, Japan. CheckMate 227 will explore this first-line combination therapy further.
The primary objective for the 56 enrolled patients with stage IIIB/IV disease was safety. Patients were randomly assigned based on histology to treatment with one of three platinum-based doublet chemotherapy groups in addition to nivolumab. All patients with squamous histology received gemcitabine/cisplatin, patients with nonsquamous histology received pemetrexed/ cisplatin, and those with any histology received paclitaxel/caboplatin.
Updated results revealed no new safety signals from the September 2014 database. The overall response rate was 46%, and the median duration of response was 10.4 months. Median overall survival was 19.2 months, with a 3-year overall survival rate of 25%.
